Enveric Biosciences, Inc. (ENVB)

NASDAQ: ENVB · Real-Time Price · USD

0.325

+0.004 (1.25%)

At close: Dec 20, 2024, 4:00 PM

0.329

+0.004 (1.35%)

After-hours: Dec 20, 2024, 6:21 PM EST

Enveric Biosciences Employees

Enveric Biosciences had 7 employees as of December 31, 2023. The number of employees decreased by 19 or -73.08% compared to the previous year.

Employees

7

Change (1Y)

-19

Growth (1Y)

-73.08%

Revenue / Employee

n/a

Profits / Employee

-$1,408,040

Market Cap

3.23M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	7	-19	-73.08%
Dec 31, 2022	26	2	8.33%
Dec 31, 2021	24	21	700.00%
Dec 31, 2020	3	-	-

Related Stocks

Company Name	Employees
Check-Cap	85
Sharps Technology	57
Aditxt	47
ReShape Lifesciences	29
Theriva Biologics	22
HeartSciences	15
Pasithea Therapeutics	8
Quoin Pharmaceuticals	4

Employee Rankings

ENVB News

19 days ago - Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds - Business Wire
26 days ago - Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior - Business Wire
5 weeks ago - Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results - Business Wire
5 weeks ago - Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002 - Business Wire
6 weeks ago - Enveric Biosciences Announces Broad Range of Patent Issuances - Business Wire
2 months ago - Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003 - Business Wire
3 months ago - Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop - Business Wire
3 months ago - Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit - Business Wire